Programme – Main Agenda Sessions
| Time | Activity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
09:00 – 13:00
|
Pre-conference sessions/meetings (by invitation only)
|
||||||||||
|
13:00 – 14:00
|
Networking Lunch for attendees
|
||||||||||
| 14:00 – 14:25 |
Opening Remarks with the Think-tank directors: Jeffrey Lazarus, Jörn Schattenburg and Naim Alkouli
|
||||||||||
| 14:30 – 15:30 |
This session will explore person-centred and preventative strategies and policies to manage the SLD public health threat. Key themes will include tackling the global obesity challenge; awareness-raising and leveraging health literacy efforts, combined with an exploration of the pivotal roles of nutrition – including access to healthy foods – and lifestyle changes in mitigating metabolic dysfunction. Participants will delve into preventive hepatology and barriers posed by the social and commercial determinants of health.
|
||||||||||
|
15:45 – 16:55
|
Coffee and Networking
|
||||||||||
| 15:45 – 16:55 |
Doubling MASH Diagnoses by 2027: A Revolution in NITs
The challenge is set to double the number of MASH diagnoses by 2027! Can cutting-edge solutions make this ambitious goal a reality? We’ll explore innovative solutions in use or development, from early-stage biomarkers and diagnostic performance in clinical trials; to the power of other advances in early detection. With a focus on NITs, the barriers and challenges to their use in the field, issues of cost-effectiveness and accessibility along with provider awareness, this session will uncover how we can tangibly revolutionise MASH diagnosis.
|
||||||||||
| 17:00 – 18:00 |
Power of Collaboration: Multidisciplinary Teams in Early Diagnosis and Risk Stratification
In an increasingly challenging healthcare ecosystem, where prevention and early detection of NCDs is key to reducing the cost-burden to health systems, interdisciplinary collaboration is the holy grail. How can hepatologists collaborate effectively with primary care physicians, other metabolic-dysfunction specialists, nurses, nutritionists and patient advocates to optimise comprehensive, coordinated care for patients living with MASLD/MASH, leveraging each other’s expertise to support, educate and empower patients? Panellists will discuss holistic care pathways; the benefits of integrating advanced, automated tools, and the challenges of embedding screening into routine primary care.
|
||||||||||
| 18:00 – 19:15 |
Networking reception for all attendees
|
||||||||||
| Time | Activity | ||
|---|---|---|---|
| 09:00 – 09:30 | Keynote Remarks | ||
| 09:30 – 10:40 | Navigating Treatments: Strategies for an Evolving Landscape The treatment landscape for fibrosing liver disease is undergoing a transformation with the emergence of innovative treatments and clinical advancements offering hope for MASLD/MASH patients. This session will discuss how industry, practitioners and patient advocates can leverage these evolving treatments with a focus on their ground‐breaking potential in liver disease and key comorbidities.
|
||
| 10:45 – 11:45 | Digital Transformation in SLD Care: Big data, AI and Personalised Solutions for Better Outcomes Discover the transformative potential of data and digital innovation in screening and managing liver disease. Our expert panel will delve into the latest in wearables, the digitally quantified self, AI‐driven solutions, lifestyle change apps and clinical decision support systems which are revolutionising detection, management, and patient outcomes, whilst integrating the latest in behavioural change theory supporting practical digital implementation.
|
||
|
11:45 – 12:00
|
Coffee and Networking | ||
|
12:00 – 13:15
|
Interactive Insights: Dynamic Open Space Session for Cutting-Edge Solutions | ||
|
13:15 – 14:15
|
Networking lunch for all attendees | ||
| 14:15 – 15:30 | Roundtable: A Deep Dive into SLD Policy and Regulatory Processes (in collaboration with EU-funded project LIVERAIM) Addressing the global public health crisis of MASLD/MASH requires effective policies and regulatory frameworks, but recognising SLD as one of the major non-communicable diseases would be a great starting point. 2025 is the year de UN High-level meeting on NCDs, and this roundtable will tackle the tough question of how to get MASLD/MASH on the menu where it counts, highlighting access to new treatments, as well as the role of payors in enabling screening and linkage to care. Delving into the complexities and barriers in drug and diagnostic approvals, SLD Think-tank discussants will discern how to shape the future of SLD management through policy innovation and regulatory advancements.
|
||
|
15:30 – 15:45
|
Coffee and Networking | ||
| 15:45 – 16:45 | Roundtable: Urban Solutions: Tackling SLD in City Environments The prevalence of steatotic liver disease is driven by sedentary lifestyles, dietary challenges and limited access to preventive care. Our expert roundtable will examine how urban settings and policies can be transformed to address this growing public health threat. Discover how to empower citizens to become more physically active, and how the MASH Cities series is leading the way, supporting cutting-edge local solutions to metabolic dysfunction and better liver health for all.
|
||
| 16:45 – 17:00 | Closing Remarks |
Programme – Main Agenda Sessions
| Time | Activity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
09:00 – 13:00
|
Pre-conference sessions/meetings (by invitation only)
|
||||||||||
|
13:00 – 14:00
|
Networking Lunch for attendees
|
||||||||||
| 14:00 – 14:25 |
Opening Remarks with the Think-tank directors: Jeffrey Lazarus, Jörn Schattenburg and Naim Alkouli
|
||||||||||
| 14:30 – 15:30 |
This session will explore person-centred and preventative strategies and policies to manage the SLD public health threat. Key themes will include tackling the global obesity challenge; awareness-raising and leveraging health literacy efforts, combined with an exploration of the pivotal roles of nutrition – including access to healthy foods – and lifestyle changes in mitigating metabolic dysfunction. Participants will delve into preventive hepatology and barriers posed by the social and commercial determinants of health.
|
||||||||||
|
15:45 – 16:55
|
Coffee and Networking
|
||||||||||
| 15:45 – 16:55 |
Doubling MASH Diagnoses by 2027: A Revolution in NITs
The challenge is set to double the number of MASH diagnoses by 2027! Can cutting-edge solutions make this ambitious goal a reality? We’ll explore innovative solutions in use or development, from early-stage biomarkers and diagnostic performance in clinical trials; to the power of other advances in early detection. With a focus on NITs, the barriers and challenges to their use in the field, issues of cost-effectiveness and accessibility along with provider awareness, this session will uncover how we can tangibly revolutionise MASH diagnosis.
|
||||||||||
| 17:00 – 18:00 |
Power of Collaboration: Multidisciplinary Teams in Early Diagnosis and Risk Stratification
In an increasingly challenging healthcare ecosystem, where prevention and early detection of NCDs is key to reducing the cost-burden to health systems, interdisciplinary collaboration is the holy grail. How can hepatologists collaborate effectively with primary care physicians, other metabolic-dysfunction specialists, nurses, nutritionists and patient advocates to optimise comprehensive, coordinated care for patients living with MASLD/MASH, leveraging each other’s expertise to support, educate and empower patients? Panellists will discuss holistic care pathways; the benefits of integrating advanced, automated tools, and the challenges of embedding screening into routine primary care.
|
||||||||||
| 18:00 – 19:15 |
Networking reception for all attendees
|
||||||||||
| Time | Activity | ||
|---|---|---|---|
| 09:00 – 09:30 | Keynote Remarks | ||
| 09:30 – 10:40 | Navigating Treatments: Strategies for an Evolving Landscape The treatment landscape for fibrosing liver disease is undergoing a transformation with the emergence of innovative treatments and clinical advancements offering hope for MASLD/MASH patients. This session will discuss how industry, practitioners and patient advocates can leverage these evolving treatments with a focus on their ground‐breaking potential in liver disease and key comorbidities.
|
||
| 10:45 – 11:45 | Digital Transformation in SLD Care: Big data, AI and Personalised Solutions for Better Outcomes Discover the transformative potential of data and digital innovation in screening and managing liver disease. Our expert panel will delve into the latest in wearables, the digitally quantified self, AI‐driven solutions, lifestyle change apps and clinical decision support systems which are revolutionising detection, management, and patient outcomes, whilst integrating the latest in behavioural change theory supporting practical digital implementation.
|
||
|
11:45 – 12:00
|
Coffee and Networking | ||
|
12:00 – 13:15
|
Interactive Insights: Dynamic Open Space Session for Cutting-Edge Solutions | ||
|
13:15 – 14:15
|
Networking lunch for all attendees | ||
| 14:15 – 15:30 | Roundtable: A Deep Dive into SLD Policy and Regulatory Processes (in collaboration with EU-funded project LIVERAIM) Addressing the global public health crisis of MASLD/MASH requires effective policies and regulatory frameworks, but recognising SLD as one of the major non-communicable diseases would be a great starting point. 2025 is the year de UN High-level meeting on NCDs, and this roundtable will tackle the tough question of how to get MASLD/MASH on the menu where it counts, highlighting access to new treatments, as well as the role of payors in enabling screening and linkage to care. Delving into the complexities and barriers in drug and diagnostic approvals, SLD Think-tank discussants will discern how to shape the future of SLD management through policy innovation and regulatory advancements.
|
||
|
15:30 – 15:45
|
Coffee and Networking | ||
| 15:45 – 16:45 | Roundtable: Urban Solutions: Tackling SLD in City Environments The prevalence of steatotic liver disease is driven by sedentary lifestyles, dietary challenges and limited access to preventive care. Our expert roundtable will examine how urban settings and policies can be transformed to address this growing public health threat. Discover how to empower citizens to become more physically active, and how the MASH Cities series is leading the way, supporting cutting-edge local solutions to metabolic dysfunction and better liver health for all.
|
||
| 16:45 – 17:00 | Closing Remarks |
